Pau Serra (IDIBAPS) i Pere Santamaria (IDIBAPS, Universitat de Calgary, Canadà) publiquen la revisió titulada “Antigen-specific therapeutic approaches for autoimmunity” (Nature Biotechnology) on expliquen quines estratègies específiques d’antigen s’estan desenvolupant actualment per al tractament de les malalties autoimmunitàries.
Abstract:
The main function of the immune system in health is to protect the host from infection by microbes and parasites. Because immune responses to nonself bear the risk of unleashing accidental immunity against self, evolution has endowed the immune system with central and peripheral mechanisms of tolerance, including regulatory T and B cells. Although the past two dècades have witnessed the successful clinical translation of a whole host of novel therapies for the treatment of chronic inflammation, the development of antigen-based approaches capable of selectively blunting autoimmune inflammation without impairing normal immunity has remained elusive. Earlier autoantigen-specific approaches employing peptides or whole antigens have evolved into strategies that seek to preferentially deliver these molecules to autoreactive T cells either indirectly, via antigenpresenting cells, or directly, via major histocompatibility complex molecules, in ways intended to promote clonal deletion and/or immunoregulation. The disease specificity, mechanistic underpinnings, developability and translational potential of many of these strategies remain unclear.
Enllaç a la publicació: https://www.nature.com/articles/s41587-019-0015-4